David Hipkiss, AlveoGene executive chair
September 14, 2023 05:22 AM EDTUpdated September 15, 02:59 AM
Startups
R&D
Cell/Gene Tx

Gene ther­a­py biotech Alveo­Gene launch­es with lentivi­ral plat­form for res­pi­ra­to­ry dis­eases

Ayisha Sharma

News Reporter

New com­pa­ny Alveo­Gene, backed by ex­perts at the UK Res­pi­ra­to­ry Gene Ther­a­py Con­sor­tium (GTC), has made its de­but with a lead pro­gram for rare res­pi­ra­to­ry …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Bio­phar­ma be­gins to con­tem­plate an RFK Jr.-in­flu­enced FDA if Trump wins

Pfiz­er shares new de­tails on obe­si­ty pipeline, hints at ‘oth­er op­por­tu­ni­ties’

GSK buys au­toim­mune T cell en­gager for $300M up­front from Chim­a­gen

No­var­tis takes $800M Mor­phoSys write­down mere months af­ter clos­ing ac­qui­si­tion

No­var­tis high­lights over­all M&A track record fol­low­ing Mor­phoSys im­pair­ment

Fol­low­ing March in­spec­tion, No­vo Nordisk's semaglu­tide man­u­fac­tur­ing fa­cil­i­ty cit­ed by FDA

A service from the Financial Times